AXSOME THERAPEUTICS, INC. Increase (Decrease) in Inventories
AXSOME THERAPEUTICS, INC. (AXSM) reported Increase (Decrease) in Inventories of $9.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was $5.89M, a 231.46% increase year-over-year.
- AXSOME THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was $3.11M, a 1149.00% increase year-over-year.
- AXSOME THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was $3.64M, a 222.41% increase year-over-year.
- AXSOME THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was $4.99M.
- AXSOME THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2025 was $10.66M.
- AXSOME THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2024 was -$744.00K, a 109.12% decline from fiscal 2023.
- AXSOME THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2023 was $8.16M, a 512.77% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2022 was $1.33M.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 6 month as first filed | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 9 month as first filed | Increase (Decrease) in Inventories 12 month | Increase (Decrease) in Inventories 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $9.00M 10-Q · filed 2026-08-10 | $12.64M derived: sum of 3 quarters · filed 2026-08-10 | $17.63M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2026-03-31 | $3.11M 10-Q · filed 2026-05-04 | $6.75M derived: sum of 2 quarters · filed 2026-05-04 | $11.74M derived: sum of 3 quarters · filed 2026-05-04 | $13.52M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-12-31 | $3.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $8.63M derived: sum of 2 quarters · filed 2026-02-23 | $10.41M derived: sum of 3 quarters · filed 2026-08-10 | $10.66M 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $4.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $6.77M derived: sum of 2 quarters · filed 2026-08-10 | $7.02M 10-Q · filed 2025-11-03 | $8.15M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-06-30 | $1.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $2.03M 10-Q · filed 2026-08-10 | $3.15M derived: sum of 3 quarters · filed 2026-08-10 | $1.87M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-03-31 | $249.00K 10-Q · filed 2026-05-04 | $1.38M derived: sum of 2 quarters · filed 2026-05-04 | $90.00K derived: sum of 3 quarters · filed 2026-05-04 | -$600.00K derived: sum of 4 quarters · filed 2026-05-04 | |||
| 2024-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$159.00K derived: sum of 2 quarters · filed 2026-02-23 | -$849.00K derived: sum of 3 quarters · filed 2026-02-23 | -$744.00K 10-K · filed 2026-02-23 | |||
| 2024-09-30 | -$1.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$1.98M derived: sum of 2 quarters · filed 2025-11-03 | -$1.87M 10-Q · filed 2025-11-03 | $3.02M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-06-30 | -$690.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | -$585.00K 10-Q · filed 2025-08-04 | $4.30M derived: sum of 3 quarters · filed 2026-02-23 | $2.64M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-03-31 | $105.00K 10-Q · filed 2025-05-05 | $4.99M derived: sum of 2 quarters · filed 2026-02-23 | $3.33M derived: sum of 3 quarters · filed 2026-02-23 | $4.64M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2023-12-31 | $4.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $3.22M derived: sum of 2 quarters · filed 2026-02-23 | $4.54M derived: sum of 3 quarters · filed 2026-02-23 | $8.16M 10-K · filed 2026-02-23 | |||
| 2023-09-30 | -$1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$352.00K derived: sum of 2 quarters · filed 2024-11-12 | $3.27M 10-Q · filed 2024-11-12 | $4.59M derived: sum of 4 quarters · filed 2025-02-18 | |||
| 2023-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $4.93M 10-Q · filed 2024-08-05 | $6.25M derived: sum of 3 quarters · filed 2025-02-18 | $6.54M derived: sum of 4 quarters · filed 2025-02-18 | |||
| 2023-03-31 | $3.62M 10-Q · filed 2024-05-06 | $4.94M derived: sum of 2 quarters · filed 2025-02-18 | $5.23M derived: sum of 3 quarters · filed 2025-02-18 | ||||
| 2022-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $1.61M derived: sum of 2 quarters · filed 2025-02-18 | $1.33M 10-K · filed 2025-02-18 | $1.33M 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $286.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $9.00K 10-Q · filed 2023-11-06 | $8.60K 10-Q · filed 2022-11-07 | ||||
| 2022-06-30 | -$277.00K 10-Q · filed 2023-08-07 | -$277.25K 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |